All In Biotech

Drug Trial Radar · NCT06805656

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Use of Antiretrovirals

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Mar 1, 2027

Study completion Jun 1, 2028

Sponsor

Lead sponsor
Federal University of São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico; Weill Medical College of Cornell University; Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in the reduction of CD4 + and CD8 + T cell activation. Combined interventions include intensified antiretroviral treatment to mitigate residual HIV replication, use of a histone deacetylase inhibitor to interrupt viral latency, use of an anti-proliferative medication to reduce long-lived T cells that harbor HIV and a personalized dendritic cell therapy vaccine to eliminate cells with latent HIV infection or cells present in viral sanctuaries. Due to the good results obtained in the exploratory stage of the project, the investigators propose to expand it by recruiting a larger number of patients to confirm the previously obtained results and to generate new insights related to the mechanisms involved in viral latency, latency disruption and the effects of analytical treatment interruption of antiretrovirals among patients undergoing all above mentioned interventions.

Conditions

  • Hiv
  • HIV I Infection

Interventions

  • MaravirocDrug

    antiretroviral intensification

  • DolutegravirDrug

    antiretroviral intensification

  • Dendritic Cell VaccineBiological

    therapeutic vaccination

  • AuranofinDrug

    purging

  • Sirtuin Histone deacetylase inhibitorDrug

    latency disruption

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evolution of viral load of HIV RNA over the time frame of studyTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  2. Evolution of total DNA and episomal HIV in PBMCsTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  3. Evolution of cell-associated HIV RNA in PBMCs over the study time frameTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  4. Evolution of total DNA and episomal HIV DNA in lymphoid tissue (rectal biopsy)Time frame: baseline, week 48, after resurgence of viremia in the analytical interruption of antiretrovirals, or after 24 and 96 weeks after analytical interruption of antiretrovirals.
  5. Evolution of the HIV DNA sequence of the V3 region of gp 120, protease, reverse transcriptase and integrase regions of the pol gene, and of the gag geneTime frame: baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART
  6. Evolution of the HIV RNA sequence of the V3 region of gp 120, protease, reverse transcriptase and integrase regions of the pol gene, and of the gag geneTime frame: baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART
  7. Evolution of CD4 + and CD8 + T lymphocyte countTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to a total of 36 months after ATI.
  8. Evolution of percentages of CD38 and HLA DR in CD4 + and CD8 + T lymphocytesTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  9. Evolution of plasma cytokines IL-2, IL-4, IL-6, IL-10, IL-17, TNF and IFN-γTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  10. Changes in bacterial translocation levels by quantification of plasma LPS levelsTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CCDI

    São Paulo, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.